cancer drug fails late-stage trial
Send a link to a friend
[August 16, 2017] (Reuters)
- Bristol-Myers Squibb Co said on Tuesday
its combination drug to treat previously untreated patients with
advanced or metastatic renal cell carcinoma, a type of kidney cancer,
failed to meet one of the main goals of a late-stage trial.
The drugmaker's shares were down 3.4 percent at $55.90 in
The combination of Bristol-Myers' two top drugs — Opdivo and Yervoy
— was not statistically significant in improving progression-free
survival in patients, when compared with standard-of-care drug
The drugmaker has been under pressure from activist investors after
falling behind Merck & Co Inc in the key field of immuno-oncology
after its Opdivo drug failed to prolong survival in previously
untreated patients with non-small cell lung cancer, the largest
Merck's rival drug, Keytruda, improved the survival rate as a
front-line treatment for non-small cell lung cancer.
Bristol-Myers said on Tuesday the combination therapy met one of the
main goals of the study. The trial would continue to evaluate the
treatment for another primary goal of overall survival.
[to top of second column]
Renal cell carcinoma is the most common type of kidney cancer in
adults, accounting for more than 100,000 deaths worldwide each year,
the company said.
(Reporting by Divya Grover in Bengaluru; Editing by Shounak Dasgupta)
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.